TerminatedPhase 3NCT00804050
Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts
Studying Myelodysplastic neoplasm with increased blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche-ETS
- Principal Investigator
- Dario Ferrero, MDUniversity of Torino - Ospedale San Giovanni Battista
- Intervention
- infusion A: rEPO(drug)
- Enrollment
- 184 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2010
Study locations (18)
- Ospedale SS. Antonio, Biagio e Cesare Arrigo, Alessandria, Italy
- Ospedale degli Infermi, Biella, Italy
- Spedali civili, Brescia, Italy
- Ospedale Santo Spirito, Casale (AL), Italy
- Ospedale Maggiore, Chieri (TO), Italy
- Policlinico dell'Annunziata, Cosenza, Italy
- Ospedale Santa Croce e Carle, Cuneo, Italy
- Ospedale Santa Croce, Fano (PU), Italy
- Ospedale San Martino, Genova, Italy
- Ospedale civile, Ivrea (TO), Italy
- Ospedale San Gerardo, Monza (MI), Italy
- Ospedale Maggiore della Carità, Novara, Italy
- Ospedale Civile, Ovada (AL), Italy
- Istituto clinico Humanitas, Rozzano (MI), Italy
- Ospedale San Giovanni Battista Molinette, Torino, Italy
- +3 more locations on ClinicalTrials.gov
Collaborators
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00804050 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with increased blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06616636A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)M.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06138587Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT04994808Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid LeukemiaFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT04741945Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDSKirsten Grønbæk
- RECRUITINGPHASE1NCT04275518A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.Ascentage Pharma Group Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT03974217Talazoparib for Cohesin-Mutated AML and MDS With Excess BlastsDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE3NCT03682536A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïveCelgene
- RECRUITINGPHASE1, PHASE2NCT03471260Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesM.D. Anderson Cancer Center
See all trials for Myelodysplastic neoplasm with increased blasts →